Can a new drug combo shrink Hard-to-Treat tumors?
NCT ID NCT06139211
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial is testing whether an experimental drug called JS015, when combined with standard chemotherapy or immunotherapy, is safe and effective for people with advanced solid tumors that have not responded to prior treatment. The study includes patients with certain cancers like esophageal and gastric cancer. The goal is to find the best dose and see if the combination can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JS015 (an experimental biologic) combined with toripalimab, paclitaxel, irinotecan, or capecitabine
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced solid tumors like esophageal, gastric, and other cancers.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the treatment may not work or may cause significant side effects. More research is needed before it could become a standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can your own immune cells beat advanced cancer?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Blood and gut clues may flag pancreatic cancer risk early
- Tumor DNA mapping may unlock personalized cancer therapies